HB1809-FN: (New Title) establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

Related law links

RSA references from bill data

• 126-Z · reference · effective 2030-11-01

  ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat

• 14:49 · reference · effective 2030-11-01

  disadvantages of the use of psilocybin for therapeutic purposes under this chapter and, if appropriate, design a program for the medical use of psilocybin. II. Notwithstanding RSA 14:49, the board shall consist of the following members: (a) The medical director of the department of health and human services, or designee. (b) A qualifying patient, appointed by the commissioner of the department of

RSAs mentioned by this document

• RSA 14 · LEGISLATIVE OFFICERS AND PROCEEDINGS
• RSA 126-Z · RIGHT TO TRY ACT
• RSA 14:49 · Legislative Study Committees and Commissions